Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-20T03:50:44.797Z Has data issue: false hasContentIssue false

40 - Gynecologic Malignancies

from PART II - CLINICAL RESEARCH

Published online by Cambridge University Press:  05 June 2012

By
Sarah M. Temkin  and
S. Diane Yamada
Edited by
David Lyden ,
Danny R. Welch  and
Bethan Psaila
Sarah M. Temkin
Affiliation:
University of Chicago Medical Center, United States
S. Diane Yamada
Affiliation:
University of Chicago Medical Center, United States
David Lyden
Affiliation:
Weill Cornell Medical College, New York
Danny R. Welch
Affiliation:
Weill Cornell Medical College, New York
Bethan Psaila
Affiliation:
Imperial College of Medicine, London
Get access

Summary

The three major classes of gynecologic malignancies include ovarian, endometrial, and cervical cancer. Although most women with ovarian cancer will present with metastatic disease (75%–80% of patients), a relatively small percentage of women with endometrial cancer have metastatic disease at diagnosis (20% of patients). For women with cervical cancer, 60 percent will have metastatic disease when they are initially diagnosed. Ovarian cancer is the most lethal of the gynecologic malignancies, as its pattern of spread is intraperitoneal and often causes the patient few readily identifiable symptoms. Endometrial cancer has the best prognosis overall, as it is usually detected at an early stage when it can be treated with surgery alone. Cervical cancer, despite its prevalence worldwide, is uncommon in the developed world and is treatable and often curable, given its sensitivity to radiation, even after locally advanced spread.

Each of the gynecologic malignancies presents the practitioner with unique clinical and treatment challenges. Advances in imaging techniques, surgical techniques, chemotherapy administration, and the development of targeted therapies have led to improved treatment options for patients diagnosed with gynecologic malignancies. This chapter highlights common patterns of metastasis for each of the major tumor types, diagnostic modalities, and the standard and emerging treatments for ovarian, endometrial, and cervical cancer.

EPITHELIAL OVARIAN CANCER

An estimated 21,550 new cases of ovarian cancer were diagnosed in 2009, with 14,600 estimated deaths, making ovarian cancer the most lethal of the gynecologic malignancies. The majority (95%) of cancers arising from the ovary are epithelial in origin.

Type
Chapter
Information
Cancer Metastasis
Biologic Basis and Therapeutics
 , pp. 440 - 455
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

,International Federation of Gynecology and Obstetrics. (1991) Annual Report on the Results of Treatment in Gynecological Cancer. 21. Stockholm: Panorama Press AB.Google Scholar
,Cancer Facts and Figures 2009 (2009).
Scully, RE (1979) Tumors of the ovary and maldeveloped gonads. In Atlas of Tumor Pathology, fasc 16, ser 2. Armed Forces Institute of Pathology, Washington, DC, pp. 1–44.Google Scholar
Hoskins, WJ, Perez, C, Young, RC, Barakat, R, Markman, M, Randall, M (2005) Principles and Practice of Gynecologic Oncology, Fourth ed. Philadelphia: Lippincott Williams & Wilkins.Google Scholar
Goff, BA, Mandel, LS, Drescher, CW et al. (2007) Development of an ovarian cancer symptom index. Cancer. 109: 221–227.CrossRefGoogle ScholarPubMed
Chambers, AF, Groom, AC, McDonald, IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer. 2: 563–572.CrossRefGoogle ScholarPubMed
Pantel, K, Brakenhoff, R (2004) Dissecting the metastatic cascade. Nature Rev Cancer. 4: 448–456.CrossRefGoogle ScholarPubMed
Cooper, BC, Sood, AK, Davis, CS et al. (2002) Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 100(1): 59–64.Google ScholarPubMed
Canney, PA, Moore, M, Wilkinson, PM, James, RD (1984) Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 50(6): 765–769.CrossRefGoogle ScholarPubMed
Bast, RC Jr, Klug, TL, St. John, E et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309(15): 883–837.CrossRefGoogle ScholarPubMed
Burghardt, E, Girardi, F, Lahousen, M, Tamussino, K, Stettner, H (1991) Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 40(2): 103–106.CrossRefGoogle ScholarPubMed
Rose, PG, Piver, MS, Tsukada, Y, Lau, TS (1989) Metastatic patterns in histologic variants of ovarian cancer: an autopsy study. Cancer. 64: 1508–1513.3.0.CO;2-V>CrossRefGoogle Scholar
Zebrowski, BK, Liu, W, Ramirez, K et al. (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 6: 373–378.CrossRefGoogle ScholarPubMed
Andus, T, Gross, V, Holstege, A et al. (1992) Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity of patients with ascites. J Hepatol. 15: 378–381.CrossRefGoogle ScholarPubMed
Behammer, W, Kluge, M, Ruschoff, J, Mannel, DN (1996) Tumor necrosis factor effects on ascites formation in an experimental tumor model. J Interferon Cytokine Res. 16: 403–408.CrossRefGoogle Scholar
Krebs, HB, Goplerud, DR (1984) The role of intestinal intubation in obstruction of the small intestine due to carcinoma of the ovary. Surg Gynecol Obstet. 158(467): 471.Google ScholarPubMed
Lund, B, Hansen, M, Lundrael, F et al. (1989) Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet. 169: 213–218.Google ScholarPubMed
Woodward, PJ, Hosseinzadeh, K, Saenger, JS (2004) From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. RadioGraphics. 24(1): 225–246.CrossRefGoogle ScholarPubMed
Forstner, R, Hricak, H, Occhipinti, K et al. (1995) Ovarian cancer: staging with CT and MRI. Radiology. 197(619): 626.CrossRefGoogle Scholar
Tempany, CM, Zou, KH, Silverman, SG, Brown, DL, Kurtz, AB, McNeil, BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiology Oncology Group. Radiology. 215(761): 767.CrossRefGoogle ScholarPubMed
Coakley, FV (2002) Staging ovarian cancer: role of imaging. Radiol Clin North Am. 40(609): 636.CrossRefGoogle ScholarPubMed
Quayyum, A, Coakley, FV, Westphalen, AC et al. (2005) Role of CT and MRI in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 96: 301–306.CrossRefGoogle Scholar
Bristow, RE, Duska, LR, Lambrou, NC et al. (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 89: 1532–1540.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Rose, PJ, Faulhaber, P, Miraldi, F et al. (2001) Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 82(117): 121.CrossRefGoogle ScholarPubMed
Murakami, M, Miyamoto, T, Iida, T et al. (2006) Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer. 16(S1): 99–107.CrossRefGoogle ScholarPubMed
Karlan, BY, Hawkins, R, Hoh, C et al. (1993) Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol. 51(175): 181.CrossRefGoogle Scholar
Hubner, KH, McDonald, TW, Niethammer, JG et al. (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F] deoxyglucose (2-[18F] FDG). Gynecol Oncol. 51: 197–204.CrossRefGoogle Scholar
Fujii, S, Matsusue, E, Kanasaki, Y et al. (2008) Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol. 18(1): 18–23.CrossRefGoogle ScholarPubMed
Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Thun, MJ (2007) Cancer statistics. CA Cancer Clin. 57: 43–66.CrossRefGoogle ScholarPubMed
Aletti, GD, Dowdy, SC, Gostoust, BS et al. (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 107: 77–85.CrossRefGoogle ScholarPubMed
Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20: 1248–1259.CrossRefGoogle ScholarPubMed
Chi, DS, Eisenhauer, EL, Lang, J et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecol Oncol. 103: 559–564.CrossRefGoogle ScholarPubMed
Eisenhauer, EL, Abu-Rustum, N, Sonoda, Y, Aghajanian, C, Barakat, R, Chi, DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 108: 276–281.CrossRefGoogle ScholarPubMed
du Bois, A, Lück, HJ, Meier, W et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 95(17): 1320–1329.CrossRefGoogle ScholarPubMed
Alberts, DS, Green, S, Hannigan, EV et al. (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 10(5): 706–717.CrossRefGoogle Scholar
Neijt, JP, Engelholm, SA, Tuxen, MK et al. (2000) Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 18(17): 3084–3092.CrossRefGoogle ScholarPubMed
Muggia, FM, Braly, PS, Brady, MF et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 18(1): 106–115.CrossRefGoogle ScholarPubMed
Alberts, DS, Liu, PY, Hannigan, EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335(26): 1950–1955.CrossRefGoogle ScholarPubMed
Markman, M, Bundy, BN, Alberts, DS et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 19(4): 1001–1007.CrossRefGoogle ScholarPubMed
Armstrong, DK, Bundy, B, Wenzel, L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354(1): 34–43.CrossRefGoogle ScholarPubMed
Elit, L, Oliver, TK, Covens, A et al. (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 109(4): 692–702.CrossRefGoogle ScholarPubMed
Jaaback, K, Johnson, N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. CD005340. Cochrane Database Syst Rev. 25(1).CrossRefGoogle Scholar
Bookman, MA, , Brady MF, McGuire, WP et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 27(9): 1419–1425.CrossRefGoogle ScholarPubMed
Markman, M, Liu, PY, Wilczynski, S et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 21 (13): 2460–2465.CrossRefGoogle Scholar
Markman, M, Liu, PY, Moon, J et al. (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114(2): 195–198.CrossRefGoogle Scholar
Klug, TL, Bast, RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr (1984) Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 44(3): 1048–1053.
Rustin, GJ, Burg, ME et al, on behalf of MRC and EORTC Collaborators. (2009) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet 376(9747): 1155–1163.CrossRefGoogle Scholar
Ferrero, JM, Weber, B, Geay, JF et al. (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann Oncol. 18(2): 263–268.CrossRefGoogle ScholarPubMed
Gordon, AN, Tonda, M, Sun, S, Rackoff, W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 95(1): 1–8.CrossRefGoogle Scholar
Gordon, AN, Fleagle, JT, Guthrie, D, Parkin, , Gore, ME, Lacave, AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 19(14): 3312–3322.CrossRefGoogle ScholarPubMed
Bolis, G, Scarfone, G, Giardina, G et al. (2001) Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 81(1): 3–9.CrossRefGoogle ScholarPubMed
Cantù, MG, Buda, A, Parma, G et al. (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 20(5): 1232–1237.CrossRefGoogle ScholarPubMed
Pfisterer, J, Plante, M, Vergote, I et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 24(29): 4699–4707.CrossRefGoogle ScholarPubMed
Parmar, MK, Ledermann, JA, Colombo, N et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361(9375): 2099–2106.Google ScholarPubMed
Chi, DS, Eisenhauer, EL, Lang, J et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecol Oncol. 103: 559–564.CrossRefGoogle ScholarPubMed
Hartenbach, EM, Olson, TA, Goswitz, JJ (1997) Vascular endothelial growth factor (VEGF) in human epithelial ovarian carcinomas. Cancer Lett. 121: 169–175.CrossRefGoogle Scholar
Yamamoto, S, Konishi, I, Mandai, M (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 76: 1221–1227.CrossRefGoogle ScholarPubMed
Rudlowski, C, Pickart, AK, Fuhljahn, C et al. (2006) Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 16(S1): 183–189.CrossRefGoogle ScholarPubMed
Numnum, TM, Rocconi, RP, Whitworth, J, Barnes, MN (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 102(3): 425–428.CrossRefGoogle ScholarPubMed
Burger, RA, Sill, MW, Monk, BJ, Greer, BE, Sorosky, JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 25(33): 5165–5171.CrossRefGoogle ScholarPubMed
Cannistra, SA, Matulonis, UA, Penson, RT et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 25(33): 5180–5186.CrossRefGoogle ScholarPubMed
Garcia, AA, Hirte, H, Fleming, G et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol. 26(1): 76–82.CrossRefGoogle ScholarPubMed
Nimeiri, HS, Oza, AM, Morgan, RJ et al. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia. Gynecol Oncol. 110(1): 49–55.CrossRefGoogle ScholarPubMed
Azad, NS, Posadas, EM, Kwitkowski, VE et al. (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 26(22): 3709–3714.CrossRefGoogle ScholarPubMed
Zorn, KK, Bonome, T, Gangi, L et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 11(18): 6422–6430.CrossRefGoogle ScholarPubMed
Tothill, RW, Tinker, AV, George, J et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14(16): 5198–5208.CrossRefGoogle ScholarPubMed
Singer, G, Oldt, R III, Cohen, Y et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 95(6): 484–486.CrossRefGoogle ScholarPubMed
Hsu, CY, Bristow, R, Cha, MS et al. (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 10(19): 6432–6436.CrossRefGoogle ScholarPubMed
Antoniou, A, Pharoah, PD, Narod, S et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72: 1117–1130.CrossRefGoogle ScholarPubMed
Farmer, H, McCabe, N, Lord, CJ et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434(7035): 917–921.CrossRefGoogle ScholarPubMed
Ashworth, A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 26(22): 3785–3790.CrossRefGoogle ScholarPubMed
Ries, LAG, Young, JLKeel, GEEisner, MPLin, YDHorner, M-J (2007) SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. No. 07-6215. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub.Google Scholar
Creasman, WT, Morrow, CP, Bundy, BN, Homesley, HD, Graham, JE, Heller, PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 60(8): 2035–2041.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Keys, HM, Roberts, JA, Brunetto, VL et al. (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 92(3): 744–751.CrossRefGoogle ScholarPubMed
Morrow, CP, Bundy, BN, Kurman, RJ et al. (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol. 40(1): 55–65.CrossRefGoogle Scholar
Fleming, GF (2007) Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 25(20): 2983–2990.CrossRefGoogle ScholarPubMed
Randall, TC, Armstrong, K (2003) Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol. 21: 4200–4206.CrossRefGoogle ScholarPubMed
Prat, J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol. 35: 649–662.CrossRefGoogle ScholarPubMed
Umpierre, SA, Burke, TW, Tornos, C et al. (1994) Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol. 17: 530–537.Google Scholar
An, HJ, Logani, S, Isacson, C, Ellenson, LH (2004) Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 17(5): 530–537.CrossRefGoogle ScholarPubMed
Yamada, SD, Burger, RA, Brewster, WR, Anton, D, Kohler, MF, Monk, BJ (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 88(12): 2782–2786.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Brooks, SE, Zhan, M, Cote, T, Baquet, CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 93: 204–208.CrossRefGoogle ScholarPubMed
McCluggage, WG (2008) Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 12: 687–690.CrossRefGoogle Scholar
Ben-Shachar, I, Pavelka, J, Cohn, et al. (2005) Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol. 105(3): 487–493.CrossRefGoogle ScholarPubMed
Temkin, SM, Hellmann, M, Lee, YC, Abulafia, O (2007) Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer. 17(1): 215–219.CrossRefGoogle ScholarPubMed
Nemani, D, Mitra, N, Guo, M, Lin, L (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 111(1): 82–88.CrossRefGoogle ScholarPubMed
Cragun, JM, Havrilesky, LJ, Calingaert, B et al. (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 23(16): 3668–3675.CrossRefGoogle ScholarPubMed
Lutman, CV, Havrilesky, LJ, Cragun, JM et al. (2006) Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 102(1): 92–97.CrossRefGoogle Scholar
Zerbe, MJ, Bristow, R, Grumbine, FC, Montz, FJ (2000) Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol. 78: 67–70.CrossRefGoogle ScholarPubMed
Hricak, H, Rubinstein, LV, Gherman, GM, Karstaedt, N (1991) MR imaging evaluation of endometrial carcinoma: results of an NCI cooperative study. Radiology. 179: 829–832.CrossRefGoogle ScholarPubMed
Park, JY, Kim, EN, Kim, DY (2008) Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol. 108: 486–492.CrossRefGoogle ScholarPubMed
Obel, J, Friberg, G, Fleming, GF (2006) Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 4(459): 468.Google ScholarPubMed
Randall, ME, Filiaci, VL, Muss, H et al. (2006) Randomized Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 24(1): 36–44.CrossRefGoogle ScholarPubMed
Thigpen, JT, Blessing, JA, DiSaia, PJ et al. (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 12(1408): 1414.CrossRefGoogle ScholarPubMed
Thigpen, JT, Brady, MF, Homesley, HD et al. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 22: 3902–3908.CrossRefGoogle ScholarPubMed
Fleming, GF, Brunetto, VL, Cella, D et al. (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Sudy. J Clin Oncol. 22: 2159–2166.CrossRefGoogle ScholarPubMed
Humber, CE, Tierney, JF, Symonds, RP et al. (2007) Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 18: 409–420.CrossRefGoogle ScholarPubMed
McMeekin, DS, Filiaci, VL, Thigpen, JT, Gallion, HH, Fleming, GF, Rodgers, WH (2007) The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 106(1): 16–22.CrossRefGoogle ScholarPubMed
Sutton, G, Brunetto, VL, Kilgore, L et al. (2000) A Phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 79(2): 147–153.CrossRefGoogle ScholarPubMed
Homesley, HD, Filiaci, V, Markman, M et al. (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 25(5): 526–531.CrossRefGoogle ScholarPubMed
Kuten, A, Grigsby, PW, Pere, CA et al. (1989) Results of radiotherapy in recurrent endometrial carcinoma. Int J Radiation Oncol Biol Phys. 17: 29–32.CrossRefGoogle ScholarPubMed
Jhingran, A, Burke, TW, Eifel, PJ et al. (2003) Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 56: 1366–1372.CrossRefGoogle ScholarPubMed
Huh, WK, Straughn, JM, Mariani, A et al. (2007) Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 17: 886–889.CrossRefGoogle Scholar
Barakat, RR, Goldman, NA, Patel, DA et al. (1999) Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 75: 99–102.CrossRefGoogle ScholarPubMed
Tangjitgamol, S, Levenback, CF, Beller, U, Kavanaugh, JJ et al. (2004) Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer. 14: 399–422.CrossRefGoogle ScholarPubMed
Awtrey, CS, Cadungog, MG, Leitao, MM et al. (2006) Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol. 102: 480–488.CrossRefGoogle ScholarPubMed
Bristow, RE, Zerbe, MJ, Rosenshein, NB, Grumbine, FC, Montz, FJ (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 78(2): 85–91.CrossRefGoogle Scholar
Memarzadeh, S, Holschneider, CH, Bristow, RE et al. (2003) FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 13(5): 664–72.Google Scholar
Winter, WE III, Maxwell, GL, Tian, C et al. (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 26(1): 83–89.CrossRefGoogle ScholarPubMed
Hecht, JL, Mutter, GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 24(29): 4783–4791.CrossRefGoogle ScholarPubMed
Kimura, F, Watanabe, J, Hata, H et al. (2004) PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol. 130(3): 161–168.CrossRefGoogle ScholarPubMed
Macwhinnie, N, Monaghan, H (2004) The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer. 14(5): 938–946.CrossRefGoogle ScholarPubMed
Matias-guiu, X, Catasus, L, Bussaglia, E et al. (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 32(6): 569–577.CrossRefGoogle ScholarPubMed
Acharya, S, Hensley, ML, Montag, AC, Fleming, GF (2005) Rare uterine cancers. Lancet Oncol. 6(12): 961–971.CrossRefGoogle ScholarPubMed
Daikoku, T, Hirota, Y, Tranguch, S et al. (2008) Conditional loss of uterine PTEN unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 68(14): 5619–5627.CrossRefGoogle ScholarPubMed
Oza, AM, Elit, L, Provencher, D et al. (2008) A Phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol. 26[20]. May 20 suppl; abstr 5516 Abstract.CrossRefGoogle Scholar
Slomovitz, BM, Lu, KH, Johnston, T et al. (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer Epub abstract.
Colombo, N, McMeekin, S, Schwartz, P et al. (2007) A Phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 25[18S] (June 20 Supplement), abstr 5516.Google Scholar
Kamat, AA, Merritt, WM, Coffey, D et al. (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 13(24): 7487–7495.CrossRefGoogle ScholarPubMed
Wright, JD, Powell, MA, Rader, JS, Mutch, DG, Gibb, RK (2007) Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res. 27: 3525–3528.Google ScholarPubMed
Aghajanian, C, Sill, MW, Darcy, K et al. (2009) A Phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol (Meeting Abstracts). 27(15S): 5531.Google Scholar
Hetzel, DJ, Wilson, TO, Keeney, GL, Roche, PC, Cha, SS, Podratz, KC (1992) HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol. 47(2): 179–185.CrossRefGoogle Scholar
Grushko, TA, Filiaci, VL, Mundt, AJ, Ridderstrsle, K, Olopade, OI, Fleming, GF (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 108(1): 3–9.CrossRefGoogle ScholarPubMed
Bosch, FX, Lorincz, A, Munoz, N, Meijer, CJLM, Shah, KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 55: 244–265.CrossRefGoogle ScholarPubMed
zur Hausen, H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2(5): 342–350.CrossRefGoogle ScholarPubMed
Scheffner, M, Werness, BA, Huibregtse, JM, Levine, AJ, Howley, PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63(6): 1129–1136.CrossRefGoogle ScholarPubMed
Chellappan, S, Kraus, VB, Munger, K, Howley, P, Phelps, WC, Nevins, JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA. 89(10): 4549–4553.CrossRefGoogle ScholarPubMed
Goff, BA, Muntz, HG, Paley, PJ, Tamimi, HK, Koh, WJ, Greer, BE (1999) Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol. 74(3): 436–442.CrossRefGoogle ScholarPubMed
Tanaka, Y, Sawada, S, Murata, T (1984) Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol. 23: 455–459.CrossRefGoogle ScholarPubMed
Gold, MA, Tian, C, Whitney, C, Rose, PG, Lanciano, R (2008) Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Cancer. 112(9): 1954–1963.CrossRefGoogle ScholarPubMed
Heller, PB, Maletano, JH, Bundy, BN, Barnhill, DR, Okagaki, T (1990) Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis – a Gynecologic Oncology Group study. Gynecol Oncol. 38: 425–430.CrossRefGoogle ScholarPubMed
Hacker, NF, Wain, GV, Nicklin, JL (1995) Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer. 5: 250–256.CrossRefGoogle ScholarPubMed
Cosin, JA, Fowler, JM, Chen, MD, Paley, PJ, Carson, LF, Twiggs, LB (1998) Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer. 82(11): 2241–2248.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Odunsi, KO, Lele, S, Ghamande, S, Seago, P, Driscoll, DL (2001) The impact of pre-therapy extraperitoneal surgical staging on the evaluation and treatment of patients with locally advanced cervical cancer. Eur J Gynaecol Oncol. 22(5): 325–30.Google ScholarPubMed
Holcomb, K, Abulafia, O, Matthews, RP, Gabbur, N, Lee, YC, Buhl, A (1999) The impact of pretreatment staging laparotomy on survival in locally advanced cervical carcinoma. Eur J Gynaecol Oncol. 20(2): 90–93.Google ScholarPubMed
Goff, BA, Muntz, HG, Paley, PJ, Tamimi, HK, Koh, WJ, Greer, BE (1999) Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol. 74(3): 436–442.CrossRefGoogle ScholarPubMed
Lai, CH, Huang, KG, Hong, J et al. (2003) Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol. 89(1): 160–167.CrossRefGoogle ScholarPubMed
Scheidler, J, Hricak, H, Yu, KK, Subak, L, Segal, MR (1997) Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA. 278: 1096–1101.CrossRefGoogle ScholarPubMed
Rose, PG, Adler, LP, Rodriguez, M, Faulhaber, PF, Abdul-Karim, FW, Miraldi, F (1999) Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. 17(1): 41.CrossRefGoogle ScholarPubMed
Grigsby, PW, Siegel, BA, Dehdashti, F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 19(17): 3745–3749.CrossRefGoogle ScholarPubMed
Boughanim, M, Leboulleux, S, Rey, A et al. (2008) Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol. 26(15): 2558–2561.CrossRefGoogle ScholarPubMed
Yen, TC, Ng, KK, Ma, SY et al. (2003) Value of dual-phase 2-fluoro-2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol. 21(19): 3651–3658.CrossRefGoogle ScholarPubMed
Rose, PG, Faulhaber, P, Miraldi, F et al. (2001) Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 82(117): 121.CrossRefGoogle ScholarPubMed
Morris, M, Eifel, PJ, Lu, J et al (1999). Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340(15): 1137–1143.CrossRefGoogle ScholarPubMed
Whitney, CW, Sause, W, Bundy, BN et al. (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17(5): 1339–1348.CrossRefGoogle ScholarPubMed
Rose, PG, Bundy, BN, Watkins, EB et al. (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340(15): 1144–1153.CrossRefGoogle ScholarPubMed
Thigpen, T, Shingleton, H, Homesley, H, Lagasse, L, Blessing, J (1981) Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Cancer. 48: 899–903.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Omura, GA, Blessing, JA, Vaccarello, L et al. (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 15: 165–171.CrossRefGoogle ScholarPubMed
Moore, DH, Blessing, JA, McQuellon, RP et al. (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 22(15): 3113–3119.CrossRefGoogle ScholarPubMed
Long, HJ III, Bundy, BN, Grendys, EC. et al. (2005) Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 23(21): 4626–4633.CrossRefGoogle ScholarPubMed
Bellone, S, Frera, G, Landolfi, G et al. (2007) Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 106(3): 513–520.CrossRefGoogle ScholarPubMed
Kim, GE, Kim, YB, Cho, NH et al. (2004) Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res. 10(4): 1366–1374.CrossRefGoogle ScholarPubMed
,ASTEC study group, Kitchener et al. (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC study), Lancet. 373(9658): 125–36.CrossRefGoogle Scholar
Naora, H, Montell, DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 5(5): 355–66.CrossRefGoogle ScholarPubMed
,International Federation of Gynecology and Obstetrics. Annual Report on the Results of Treatment in Gynecological Cancer. 21. 1991. Stockholm, Panorama Press AB. Ref Type: Report.Google Scholar
Hartenbach, EM, Olson, TA, Goswitz, JJ (1997) Vascular endothelial growth factor (VEGF) in human epithelial ovarian carcinomas. Cancer Lett. 121: 169–75.CrossRefGoogle Scholar
Creasman, WT, Morrow, CP, Bundy, BN, Homesley, HD, Graham, JE, Heller, PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 60(8): 2035–41.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Rini, BI (2008) Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 14(5): 1286–90.CrossRefGoogle ScholarPubMed
zur Hausen, H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2(5): 342–50.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×